A warning letter the US Food and Drug Administration recently sent to Yino Inc. of Chongqing, China, is the latest in a series of actions the agency has taken to protect US patients and consumers from certain quality risks associated with opaque pharmaceutical supply chains.
Francis Godwin, director of the Office of Manufacturing Quality in the FDA’s Center for Drug Evaluation and Research, told the Pink Sheet that the effort appears to be making supply
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?